Lineage Cell Therapeutics
LCTX
LCTX
113 hedge funds and large institutions have $94.2M invested in Lineage Cell Therapeutics in 2024 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 35 increasing their positions, 26 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
32% less capital invested
Capital invested by funds: $138M → $94.2M (-$44.1M)
Holders
113
Holding in Top 10
3
Calls
$100K
Puts
–
Top Buyers
| 1 | +$1.14M | |
| 2 | +$1.06M | |
| 3 | +$643K | |
| 4 |
State Street
Boston,
Massachusetts
|
+$385K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$342K |
Top Sellers
| 1 | -$1.55M | |
| 2 | -$1.23M | |
| 3 | -$692K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$327K |
| 5 |
Squarepoint
New York
|
-$147K |